본문 바로가기
KERD
논문KCI 등재

Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?

Yun-Sil Lee|서준호
대한골대사학회 (The Korean Society of Bone Metabolism)|2020.08|대한골대사학회지 (Journal of Bone Metabolism)|제27권 제3호|pp. 151-165|DOI 10.11005/jbm.2020.27.3.151

2

조회

0

다운로드

7

인용

0

참고문헌

주제분류정형외과학

초록

Myostatin, also known as growth differentiation factor 8 (GDF8), is a transforming growth factor-β (TGF-β) family member that functions to limit skeletal muscle growth. Accordingly, loss-of-function mutations in myostatin result in a dramatic increase in muscle mass in humans and various animals, while its overexpression leads to severe muscle atrophy. Myostatin also exerts a significant effect on bone metabolism, as demonstrated by enhanced bone mineral density and bone regeneration in myostatin null mice. The identification of myostatin as a negative regulator of muscle and bone mass has sparked an enormous interest in developing myostatin inhibitors as therapeutic agents for treating a variety of clinical conditions associated with musculoskeletal disorders. As a result, various myostatin-targeting strategies involving antibodies, myostatin propeptides, soluble receptors, and endogenous antagonists have been generated, and many of them have progressed to clinical trials. Importantly, most myostatin inhibitors also repress the activities of other closely related TGF-β family members including GDF11, activins, and bone morphogenetic proteins (BMPs), increasing the potential for unwanted side effects, such as vascular side effects through inhibition of BMP 9/10 and bone weakness induced by follistatin through antagonizing several TGF-β family members. Therefore, a careful distinction between targets that may enhance the efficacy of an agent and those that may cause adverse effects is required with the improvement of the target specificity. In this review, we discuss the current understanding of the endogenous function of myostatin, and provide an overview of clinical trial outcomes from different myostatin inhibitors.

Abstract

Myostatin, also known as growth differentiation factor 8 (GDF8), is a transforming growth factor-β (TGF-β) family member that functions to limit skeletal muscle growth. Accordingly, loss-of-function mutations in myostatin result in a dramatic increase in muscle mass in humans and various animals, while its overexpression leads to severe muscle atrophy. Myostatin also exerts a significant effect on bone metabolism, as demonstrated by enhanced bone mineral density and bone regeneration in myostatin null mice. The identification of myostatin as a negative regulator of muscle and bone mass has sparked an enormous interest in developing myostatin inhibitors as therapeutic agents for treating a variety of clinical conditions associated with musculoskeletal disorders. As a result, various myostatin-targeting strategies involving antibodies, myostatin propeptides, soluble receptors, and endogenous antagonists have been generated, and many of them have progressed to clinical trials. Importantly, most myostatin inhibitors also repress the activities of other closely related TGF-β family members including GDF11, activins, and bone morphogenetic proteins (BMPs), increasing the potential for unwanted side effects, such as vascular side effects through inhibition of BMP 9/10 and bone weakness induced by follistatin through antagonizing several TGF-β family members. Therefore, a careful distinction between targets that may enhance the efficacy of an agent and those that may cause adverse effects is required with the improvement of the target specificity. In this review, we discuss the current understanding of the endogenous function of myostatin, and provide an overview of clinical trial outcomes from different myostatin inhibitors.

참고문헌 (100)

  1. McPherron AC, "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member", Nature, 387, pp.83~90 (1997)
  2. Schuelke M, "Myostatin mutation associated with gross muscle hypertrophy in a child", N Engl J Med, 350, pp.2682~2688 (2004)
  3. McPherron AC, "Double muscling in cattle due to mutations in the myostatin gene", Proc Natl Acad Sci U S A, 94, pp.12457~12461 (1997)
  4. Clop A, "A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep", Nat Genet, 38, pp.813~818 (2006)
  5. Mosher DS, "A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs", PLoS Genet, 3, pp.e79~ (2007)
  6. Suh J, "GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN", GDF11 inhibitor, increases muscle mass but weakens bone, 2020, pp.117, 4910~4920
  7. Dankbar B, "Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice", Nat Med, 21, pp.1085~1090 (2015)
  8. Kellum E, "Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume", Bone, 44, pp.17~23 (2009)
  9. Rodgers BD, "Reduced circulating GDF11 is unlikely responsible for age-dependent changes in mouse heart, muscle, and brain", Endocrinology, 156, pp.3885~3888 (2015)
  10. Egerman MA, "GDF11 increases with age and inhibits skeletal muscle regeneration", Cell Metab, 22, pp.164~174 (2015)
  11. Souza TA, "Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators", Mol Endocrinol, 22, pp.2689~2702 (2008)
  12. Lee SJ, "Regulation of myostatin activity and muscle growth", Proc Natl Acad Sci U S A, 98, pp.9306~9311 (2001)
  13. Goldspink G, "Changes in rodent muscle fibre types during post-natal growth, undernutrition and exercise", J Physiol, 296, pp.453~469 (1979)
  14. Manceau M, "Myostatin promotes the terminal differentiation of embryonic muscle progenitors", Genes Dev, 22, pp.668~681 (2008)
  15. Whittemore LA, "Inhibition of myostatin in adult mice increases skeletal muscle mass and strength", Biochem Biophys Res Commun, 300, pp.965~971 (2003)
  16. Zimmers TA, "Induction of cachexia in mice by systemically administered myostatin", Science, 296, pp.1486~1488 (2002)
  17. Reardon KA, "Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy", Muscle Nerve, 24, pp.893~899 (2001)
  18. Zachwieja JJ, "Plasma myostatin-immunoreactive protein is increased after prolonged bed rest with low-dose T3 administration", J Gravit Physiol, 6, pp.11~15 (1999)
  19. Morissette MR, "Effects of myostatin deletion in aging mice", Aging Cell, 8, pp.573~583 (2009)
  20. Hamrick MW, "Increased bone mineral density in the femora of GDF8 knockout mice", Anat Rec A Discov Mol Cell Evol Biol, 272, pp.388~391 (2003)
  21. Nicholson EK, "Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice", Arch Oral Biol, 51, pp.37~49 (2006)
  22. Mitchell AD, "In vivo evaluation of changes in body composition of transgenic mice expressing the myostatin pro domain using dual energy X-ray absorptiometry", Growth Dev Aging, 70, pp.25~37 (2007)
  23. Zhang ZL, "Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families", Osteoporos Int, 19, pp.39~47 (2008)
  24. Hamrick MW, "Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise", J Bone Miner Res, 21, pp.477~483 (2006)
  25. Qin Y, "Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218 : A novel mechanism in muscle-bone communication", J Biol Chem, 292, pp.11021~11033 (2017)
  26. Hamrick MW, "Loss of myostatin(GDF8)function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading", Bone, 40, pp.1544~1553 (2007)
  27. McPherron AC, "Suppression of body fat accumulation in myostatin-deficient mice", J Clin Invest, 109, pp.595~601 (2002)
  28. Pan H, "Association of myostatin gene polymorphisms with obesity in Chinese north Han human subjects", Gene, 494, pp.237~241 (2012)
  29. Wolfman NM, "Activation of latent myostatin by the BMP-1", tolloid family of metalloproteinases, 2003, pp.100, 15842~15846
  30. Hill JJ, "The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum", J Biol Chem, 277, pp.40735~40741 (2002)
  31. Zhu X, "Dominant negative myostatin produces hypertrophy without hyperplasia in muscle", FEBS Lett, 474, pp.71~75 (2000)
  32. Lee SJ, "Genetic analysis of the role of proteolysis in the activation of latent myostatin", PLoS One, 3, pp.e1628~ (2008)
  33. Collins-Hooper H, "Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice", J Gerontol A Biol Sci Med Sci, 69, pp.1049~1059 (2014)
  34. Rebbapragada A, "Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis", Mol Cell Biol, 23, pp.7230~7242 (2003)
  35. Langley B, "Myostatin inhibits myoblast differentiation by down-regulating MyoD expression", J Biol Chem, 277, pp.49831~49840 (2002)
  36. Sartori R, "Smad2 and 3 transcription factors control muscle mass in adulthood", Am J Physiol Cell Physiol, 296, pp.C1248~C1257 (2009)
  37. Lee SJ, "Regulation of muscle growth by multiple ligands signaling through activin type II receptors", Proc Natl Acad Sci U S A, 102, pp.18117~18122 (2005)
  38. DiGirolamo DJ, "Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta", Bone Res, 3, pp.14042~ (2015)
  39. Walker RG, "Biochemistry and biology of GDF11 and myostatin : Similarities, differences, and questions for future investigation", Circ Res, 118, pp.1125~1141 (2016)
  40. Lee SJ, "Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways", PLoS One, 2, pp.e789~ (2007)
  41. Monestier O, "Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype", BMC Genomics, 13, pp.541~ (2012)
  42. Parenté A, "GASP-2 overexpressing mice exhibit a hypermuscular phenotype with contrasting molecular effects compared to GASP-1 transgenics", FASEB J, 34, pp.4026~4040 (2020)
  43. Anderson SB, "Identification of a novel pool of extracellular pro-myostatin in skeletal muscle", J Biol Chem, 283, pp.7027~7035 (2008)
  44. Li Y, "Decorin gene transfer promotes muscle cell differentiation and muscle regeneration", Mol Ther, 15, pp.1616~1622 (2007)
  45. Lee SJ, "Regulation of muscle mass by follistatin and activins", Mol Endocrinol, 24, pp.1998~2008 (2010)
  46. Lee YS, "Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2", Proc Natl Acad Sci U S A, 110, pp.E3713~E3722 (2013)
  47. Haidet AM, "Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors", Proc Natl Acad Sci U S A, 105, pp.4318~4322 (2008)
  48. Lerch TF, "Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions", J Biol Chem, 282, pp.15930~15939 (2007)
  49. Schneyer AL, "Differential distribution of follistatin isoforms : application of a new FS315-specific immunoassay", J Clin Endocrinol Metab, 89, pp.5067~5075 (2004)
  50. Campbell C, "Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial", Muscle Nerve, 55, pp.458~464 (2017)
  51. van den Berg LE, "Low bone mass in Pompe disease : muscular strength as a predictor of bone mineral density", Bone, 47, pp.643~649 (2010)
  52. Khatri IA, "Low bone mineral density in spinal muscular atrophy", J Clin Neuromuscul Dis, 10, pp.11~17 (2008)
  53. Söderpalm AC, "Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy", Neuromuscul Disord, 17, pp.919~928 (2007)
  54. Pearsall RS, "A soluble activin type IIA receptor induces bone formation and improves skeletal integrity", Proc Natl Acad Sci U S A, 105, pp.7082~7087 (2008)
  55. Lotinun S, "A soluble activin receptor Type IIA fusion protein(ACE-011)increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys", Bone, 46, pp.1082~1088 (2010)
  56. Ruckle J, "Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women", J Bone Miner Res, 24, pp.744~752 (2009)
  57. Abdulkadyrov KM, "Sotatercept in patients with osteolytic lesions of multiple myeloma", Br J Haematol, 165, pp.814~823 (2014)
  58. Tauer JT, "Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta", Bone, 128, pp.115036~ (2019)
  59. Bogdanovich S, "Functional improvement of dystrophic muscle by myostatin blockade", Nature, 420, pp.418~421 (2002)
  60. Singh P, "Translational pharmacokinetic", pharmacodynamic analysis of MYO-029 antibody for muscular dystrophy, 2016, pp.9, 302~310
  61. St Andre M, "A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys", Skelet Muscle, 7, pp.25~ (2017)
  62. Bhattacharya I, "Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects", Clin Pharmacol Drug Dev, 7, pp.484~497 (2018)
  63. Walpurgis K, "Detection of the myostatin-neutralizing antibody Domagrozumab in serum by means of Western blotting and LC-HRMS", Drug Test Anal, 11, pp.1714~1723 (2019)
  64. Becker C, "Myostatin antibody(LY2495655)in older weak fallers : a proof-of-concept, randomised, phase 2 trial", Lancet Diabetes Endocrinol, 3, pp.948~957 (2015)
  65. Woodhouse L, "A phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty", J Frailty Aging, 5, pp.62~70 (2016)
  66. Golan T, "LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial", J Cachexia Sarcopenia Muscle, 9, pp.871~879 (2018)
  67. Latres E, "Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice", Skelet Muscle, 5, pp.34~ (2015)
  68. Pirruccello-Straub M, "Blocking extracellular activation of myostatin as a strategy for treating muscle wasting", Sci Rep, 8, pp.2292~ (2018)
  69. Long KK, "Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy", Hum Mol Genet, 28, pp.1076~1089 (2019)
  70. Zhang L, "Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease", FASEB J, 25, pp.1653~1663 (2011)
  71. Desgeorges MM, "Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke", Sci Rep, 7, pp.14000~ (2017)
  72. Zhu Y, "LC-MS", MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin, 2016, pp.8, 193~204
  73. Morvan F, "Blockade of activin type II receptors with a dual anti-ActRIIA", IIB antibody is critical to promote maximal skeletal muscle hypertrophy, 2017, pp.114, 12448~12453
  74. Amato AA, "Treatment of sporadic inclusion body myositis with bimagrumab", Neurology, 83, pp.2239~2246 (2014)
  75. Hanna MG, "Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial", Lancet Neurol, 18, pp.834~844 (2019)
  76. Rooks D, "Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study", J Am Geriatr Soc, 65, pp.1988~1995 (2017)
  77. Rooks DS, "Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy", J Cachexia Sarcopenia Muscle, 8, pp.727~734 (2017)
  78. Polkey MI, "Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial", Am J Respir Crit Care Med, 199, pp.313~320 (2019)
  79. Cadena SM, "Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type", J Appl Physiol(1985), 109, pp.635~642 (2010)
  80. Attie KM, "A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers", Muscle Nerve, 47, pp.416~423 (2013)
  81. Pearsall RS, "Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease", Sci Rep, 9, pp.11392~ (2019)
  82. Glasser CE, "Locally acting ACE-083 increases muscle volume in healthy volunteers", Muscle Nerve, 57, pp.921~926 (2018)
  83. Kota J, "Follistatin gene delivery enhances muscle growth and strength in nonhuman primates", Sci Transl Med, 1, pp.6ra15~ (2009)
  84. Mendell JR, "A phase 1", 2a follistatin gene therapy trial for becker muscular dystrophy, 2015, pp.23, 192~201
  85. Mendell JR, "Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes", Mol Ther, 25, pp.870~879 (2017)
  86. Suragani RN, "Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis", Nat Med, 20, pp.408~414 (2014)
  87. Dussiot M, "An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia", Nat Med, 20, pp.398~407 (2014)
  88. Komrokji R, "Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial", Lancet Haematol, 5, pp.e63~e72 (2018)
  89. Cappellini MD, "Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study", Haematologica, 104, pp.477~484 (2019)
  90. Yung LM, "ACTRIIA-Fc rebalances activin", GDF versus BMP signaling in pulmonary hypertension, 2020, pp.12, eaaz5660~
  91. Piga A, "Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia", Blood, 133, pp.1279~1289 (2019)
  92. Cappellini MD, "A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia", N Engl J Med, 382, pp.1219~1231 (2020)
  93. Markham A, "Luspatercept : First approval", Drugs, 80, pp.85~90 (2020)
  94. Garito T, "Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals", Diabetes Obes Metab, 20, pp.94~102 (2018)
  95. Hinck AP, "Structural biology and evolution of the TGF-β family", Cold Spring Harb Perspect Biol, 8, pp.a022103~ (2016)
  96. Mathews LS, "Cloning of a second type of activin receptor and functional characterization in Xenopus embryos", Science, 255, pp.1702~1705 (1992)
  97. Phillips DJ, "Follistatin : a multifunctional regulatory protein", Front Neuroendocrinol, 19, pp.287~322 (1998)
  98. Guerra A, "Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia", Blood, 134, pp.568~572 (2019)
  99. Wagner KR, "A phase I", IItrial of MYO-029 in adult subjects with muscular dystrophy, 2008, pp.63, 561~571
  100. Fenaux P, "Luspatercept in patients with lower-risk myelodysplastic syndromes", N Engl J Med, 382, pp.140~151 (2020)

관련 논문AI추천

Myostatin Function during In Vitro Myogenesis: Considerations for Knockout-Based Mechanistic AnalysisYun-Sil Lee대한골대사학회 · 대한골대사학회지2025 · 제32권 제4호Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1- Associated Sarcopenia and Metabolic DisordersYun-Sil Lee대한골대사학회 · 대한골대사학회지2025 · 제32권 제4호A Myostain-like Gene Expressed Highly in the Muscle Tissue of Chinese mitten crab, Eriocheir sinensis김경선, 김현우, 전정민한국수산과학회 · Fisheries and Aquatic Sciences2009 · 제12권 제3호BMPs and their clinical potentials최승현, Meejung Kim생화학분자생물학회 · BMB Reports2011 · 제44권 제10호Interaction between Muscle and BoneHiroshi Kaji대한골대사학회 · 대한골대사학회지2014 · 제21권 제1호Genetic variants of the growth differentiation factor 8 affect body conformation traits in Chinese Dabieshan cattleJia Yutang, Jin Hai, Xu Lei, Zhao Shuanping아세아·태평양축산학회 · Animal Bioscience2022 · 제35권 제4호

이 간행물의 다른 논문 (6건)

Does Teriparatide Improve Fracture Union?: A Systematic Review김기철, Byung-Ho Yoonpp. 167-174Use of Bisphosphonates, Calcium and Vitamin D for Bone Demineralization in Patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome: A Systematic Review and Meta-Analysis of Clinical TrialsCarla Ormundo Gonçalves Ximenes Lima, Rocha Vinícius Magno da, Mariana Balardino Bogado Faria, Francisco de Assis dos Reis Júnior, Rossano Kepler Alvim Fiorelli, Keila Mara Cassianopp. 175-186What is the Role of Coordinators in the Secondary Fracture Prevention Program?Yong-Chan Ha, Ki Soo Park, Yong-Chan Ha, 유준일pp. 187-199Physicians’ Attitudes on Management of Osteopenia in South Korea이영균, 구경회, Joo Hyung Ha, Hong Seok Kim, Samuel Jaeyoon Wonpp. 201-205Bone Mineral Density in Diabetes Mellitus Foot Patients for Prediction of Diabetic Neuropathic Osteoarthropathic Fracture박수연, 민태홍, 이영, Dong-Il Chun, Sung Hun Won, Kwonwoo Kim, Jae-Ho Chopp. 207-215
원문 보기